Cyclacel R&D Day: Program Update on Cyclacel’s Oral CDK2/9 and PLK1 Inhibitors in Solid Tumors and Lymphoma
About The Event
Join us for an R&D Day with Cyclacel Pharmaceuticals, featuring renowned key opinion leaders in oncology and a program update from senior management.
- Jasmine Zain, MD (City of Hope National Medical Center) will be providing an overview of the unmet medical needs in the treatment of T cell lymphoma.
- Do-Youn Oh, MD, PhD (Seoul National University) will discuss unmet medical needs and current treatment options for hepatobiliary cancers.
The Cyclacel leadership team will then provide a program update on the company’s pipeline, highlighting patient data from the 065-101 oral fadraciclib Phase 1/2 study in solid tumors and lymphoma. They will also provide an update on the progress of the oral PLK1 inhibitor CYC140 in a Phase 1/2 study as a potential treatment for solid tumors and lymphoma.
A live Q&A session will follow the formal presentations.